ColinDWeekesMD

Oncology • Boston, MA

Assistant Professor, Medicine, University of Colorado School of Medicine

Join to view full profile

Dr. Weekes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Weekes' full profile

Already have an account?

Office
55 Fruit Street
Boston, MA 02114
Phone+1 617-724-4000

Fax+1 617-726-0452

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Alabama Medical CenterResidency, Internal Medicine, 2000 - 2003
University of Nebraska College of MedicineClass of 2000

Certifications & Licensure

MA State Medical License 2017 - 2026
CO State Medical License 2007 - 2019
MD State Medical License 2003 - 2007
AL State Medical License 2001 - 2003
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery Start of enrollment: 2013 Jan 15
Completed
Phase 1
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Start of enrollment: 2014 Feb 05
Completed
Phase 2
Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 1
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates Start of enrollment: 2016 Dec 30
Active, not recruiting
Phase 2
A Study of LY2510924 and Durvalumab in Participants With Solid Tumors Start of enrollment: 2016 Sep 01
Terminated
Phase 1
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Start of enrollment: 2017 Jan 12
Completed
Phase 2
A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors Start of enrollment: 2021 Jun 15
Recruiting
Phase 1, Phase 2
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells Start of enrollment: 2021 Jan 13
Recruiting
Phase 1
Roles: Contact, Principal Investigator
FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer Start of enrollment: 2022 Mar 21
Recruiting
Phase 2
Roles: Contact, Principal Investigator, Sponsor-Investigator
FOLFIRINOX + NIS793 in Pancreatic Cancer Start of enrollment: 2022 Aug 09
Recruiting
Phase 1
Roles: Principal Investigator, Sponsor-Investigator, Contact
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors Start of enrollment: 2021 Oct 04
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors Start of enrollment: 2023 Apr 14
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Establishing a Role for Local Therapy in Oligometastatic Pancreatic Cancer.
Hannah J Roberts, Colin D Weekes, Jennifer Y Wo
Journal of Clinical Oncology. 2024-11-10
A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors.
Gregory M Cote, Bose S Kochupurakkal, Khanh Do, Andrea Bullock, Michael L Cheng
Clinical Cancer Research. 2024-10-25
The Sequencing Conundrum in Localized Pancreatic Adenocarcinoma-Progress or Passive Acceptance?
Priyadarshini Pathak, Colin D Weekes, Rachna T Shroff
JAMA Oncology. 2024-08-01

Press Mentions

Actuate Therapeutics Announces Initiation of a Multicenter Randomized Trial of Elraglusib plus FOLFIRINOX as First Line Therapy for Advanced Pancreatic CancerFebruary 7th, 2022
Hold off on Approving Anal Cancer Drug, Advisors Tell FDAJune 24th, 2021
FDA Panel: Yank Keytruda Approval in Third-Line Gastric CancerApril 29th, 2021
Join now to see all